BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that members of the KemPharm team will attend the upcoming Niemann Pick Disease Foundation’s Family Support and Medical Conference.

Within days of Health Canada issuing an Interim Order authorization for the Sal6830 SARS-CoV-2 Saliva Testing Kits, a Canadian family is grateful for a non-invasive testing option that offers the accuracy of PCR in less than 30 minutes.

Gracell Biotechnologies Inc. today announced that the management team will participate in BTIG 2022 Hybrid Biotechnology Conference in August 2022.

Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior safety and efficacy of its Uttroside-B chemotherapeutic to treat liver cancer vs the current first line FDA approved drug.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2022 financial results after market close on Tuesday, August 2 , 2022.

Ecolab Second Quarter Reported Diluted EPS $1.08; Adjusted Diluted EPS $1.10; Expect Improved Second Half 2022 Performance.

Exo (pronounced “echo”), a pioneering health information and medical devices company, today announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use.

HeartBeam, Inc . (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday August 11, 2022 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones.